NYCRIS logo - click to reload menu
Taxanes Audit Lung Audit Thyroid Audit Prostate Audit Audit Projects

Radical Therapies for
Localised Prostate Cancer

Copyright NYCRIS 2001. Extracts from these pages may be reproduced provided the source is fully acknowledged.   Return to AUDIT PROJECTS.


Prostate Audit Report
26 Mar 2004 Executive Report
26 Mar 2004 - Prostate Cancer Overview
26 Mar 2004 - Acknowledgements
26 Mar 2004 - Additional Analyses (Appendices)
26 Mar 2004 - Evaluation Form (to fax or send back)


Calendar of Events
09 Dec 2002 - Steering Group Meeting - Agenda - Notes - Presentation
07 Nov 2001 - UK Association of Cancer Registries - Pilot Results
03 Oct 2001 - Steering Group Meeting - Agenda - Notes - Presentation1 - 2
18 Dec 2000 - Steering Group Meeting - Agenda - Notes
16 Oct 2000 - Steering Group Meeting - Agenda - Notes


Documentation
13 Jan 2003 - Analysis Plan
03 Oct 2001 - Analysis Notes
17 Aug 2001 - Data Collection Proforma  (final)
13 Aug 2001 - Analysis Notes
10 Jan 2001 - Protocol  (final draft)


Summary

This audit is looking at the management of patients with prostate cancer in the Northern and Yorkshire region, with a specific focus upon the management of those patients with localised disease. The treatments investigated are a) radical prostatectomy, b) external beam radiotherapy, c) brachytherapy, d) watchful waiting, e) hormonal treatment, and f) other treatments, ascertained by retrospective review.

The rationale agreed at the start of the project is given below.

Prostate cancer is the second most common cancer amongst men in Britain and there is evidence that its incidence is rising. The management of prostate cancer is a very controversial area. In a high percentage of patients the disease is localised, and radical prostatectomy or radiotherapy may achieve a cure. There may be significant unwanted side effects from radical therapy which may not be acceptable to many men.

Patient choice has a strong influence, and the patient needs to weigh up the advantages of treatments against the potential unwanted side effects. It is therefore important that the patient is provided with all the information he needs and is counselled appropriately. Additionally, uncertainty about the optimal treatment of prostate cancer may have resulted in considerable variation in practice.

top of page